Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Saison, Julien ^a,b   Cotte, Laurent ^a,b,c   Chidiac, Christian ^a,b,c   Ferry, Tristan ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; DIDANOSINE; DIURETIC AGENT; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RALTEGRAVIR; VITAMIN D; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ADVERSE OUTCOME; ARTICLE; ASCITES; CACHEXIA; CALORIMETRY; CASE REPORT; CHOLESTASIS; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DUODENUM BIOPSY; ESOPHAGUS VARICES; GASTRITIS; GASTROSCOPY; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; ILEITIS; INTRAHEPATIC CHOLESTASIS; LABORATORY TEST; LIPOATROPHY; LIPODYSTROPHY; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HYPERPLASIA; MAINTENANCE DRUG DOSE; MALE; OSTEOPOROSIS; PHYSICAL EXAMINATION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; VIRUS LOAD; WHOLE BODY CT;

EID: 84858981993     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.10.2011.4905     Document Type: Article

References (25)

1. Bhaskaran K, Hamouda O, Sannes M, et al.; CASCADE Collaboration. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-9. (Pubitemid 351920404)
2. Carr A, S amaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
3. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16. (Pubitemid 30459502)
4. Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13. (Pubitemid 350301936)
5. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165-74. (Pubitemid 44684707)
6. CDC. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after hiv exposures-worldwide, 1997-2000. Morb Mortal Wkly Rep 2001;49:1153-6.
7. Abrescia N, D 'Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. J Antimicrob Chemother 2002;50:763-5.
8. Cotte L, Bénet T, Billioud C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol 2011;54:489-96.
9. Kovari H, Ledergerber B, Peter U, et al.;Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49:626-35.
10. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010;51:591-9.
11. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28.
12. Moyle GJ, Sabin CA, Cartledge J, et al.;RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-50. (Pubitemid 44611057)
13. Grund B, Peng G, Gibert CL, et al.;I NSIGHT SMART Body Composition Substudy Group. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009;23:1519-29.
14. Rapport yeni 2010, prise en charge des patients infectes par le vih, editions flammarion, 2010.
15. Podcast for healthcare professionals: serious liver disorder associated with the use of videx/videx ec. FDA, 2010.
16. Mallet VO, V arthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009;23:1511-8.
17. Schiano TD, Uriel A, Dieterich DT, et al. The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV. Virchows Arch 2011;458:231-5.
18. Steiner PE. Nodular regenerative hyperplasia of the liver. Am J Pathol 1959;35:943-53.
19. Hofmaenner D, Kovari H, Weber A, et al. Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption. BMJ Case Reports 2011 ;doi:10.1136/bcr.03.2011.3928.
20. Bihl F, Janssens F, Boehlen F, et al. Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterol 2010;10:6.
21. Tateo M, Sebagh M, Bralet MP, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008;14:1194-8.
22. Lucignani G, Orunesu E, Cesari M, et al. F DG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging 2009;36:640-7.
23. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006;20:985-93.
24. Georgopoulos P, Mowat C, McMillan DC, et al. Is portal hypertension associated with protein-losing enteropathy? J Gastroenterol Hepatol 2005;20:103-7. (Pubitemid 40143641)
25. Wong WM, Hui CK, Yuen MF, et al. Reversal of protein-losing enteropathy by liver transplantation. J Clin Gastroenterol 2003;36:86-7.